Indirect hyperbilirubinemia with indinavir

P. Satija; Falguni Parikh; V. Aggarwal; B. Sharma; Avi Hakim; J. V. Pai-Dhungat

Indirect hyperbilirubinemia with indinavir

P. Satija, Falguni Parikh, V. Aggarwal, B. Sharma, Avi Hakim, J. V. Pai-Dhungat

Houston Methodist

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Indinavir is a protease inhibitor used in the treatment of HIV infected individuals and as post-exposure prophylaxis. Indinavir is associated with various adverse effects including gastrointestinal, a lipodystrophy syndrome and nephrolithiasis. We describe indirect hyperbilirubinemia as an adverse effect of indinavir in a person on post-exposure prophylaxis (PEP).

Original language	English (US)
Pages (from-to)	1316-1317
Number of pages	2
Journal	Journal of Association of Physicians of India
Volume	50
Issue number	10
State	Published - Oct 2002

ASJC Scopus subject areas

General Medicine

Cite this

@article{f6da45fb80f041ddab52e2427ce8b817,

title = "Indirect hyperbilirubinemia with indinavir",

abstract = "Indinavir is a protease inhibitor used in the treatment of HIV infected individuals and as post-exposure prophylaxis. Indinavir is associated with various adverse effects including gastrointestinal, a lipodystrophy syndrome and nephrolithiasis. We describe indirect hyperbilirubinemia as an adverse effect of indinavir in a person on post-exposure prophylaxis (PEP).",

author = "P. Satija and Falguni Parikh and V. Aggarwal and B. Sharma and Avi Hakim and Pai-Dhungat, \{J. V.\}",

year = "2002",

month = oct,

language = "English (US)",

volume = "50",

pages = "1316--1317",

journal = "Journal of Association of Physicians of India",

issn = "0004-5772",

publisher = "Journal of Association of Physicians of India",

number = "10",

}

TY - JOUR

T1 - Indirect hyperbilirubinemia with indinavir

AU - Satija, P.

AU - Parikh, Falguni

AU - Aggarwal, V.

AU - Sharma, B.

AU - Hakim, Avi

AU - Pai-Dhungat, J. V.

PY - 2002/10

Y1 - 2002/10

N2 - Indinavir is a protease inhibitor used in the treatment of HIV infected individuals and as post-exposure prophylaxis. Indinavir is associated with various adverse effects including gastrointestinal, a lipodystrophy syndrome and nephrolithiasis. We describe indirect hyperbilirubinemia as an adverse effect of indinavir in a person on post-exposure prophylaxis (PEP).

AB - Indinavir is a protease inhibitor used in the treatment of HIV infected individuals and as post-exposure prophylaxis. Indinavir is associated with various adverse effects including gastrointestinal, a lipodystrophy syndrome and nephrolithiasis. We describe indirect hyperbilirubinemia as an adverse effect of indinavir in a person on post-exposure prophylaxis (PEP).

UR - https://www.scopus.com/pages/publications/0036824398

UR - https://www.scopus.com/inward/citedby.url?scp=0036824398&partnerID=8YFLogxK

M3 - Article

C2 - 12568221

AN - SCOPUS:0036824398

SN - 0004-5772

VL - 50

SP - 1316

EP - 1317

JO - Journal of Association of Physicians of India

JF - Journal of Association of Physicians of India

IS - 10

ER -

Indirect hyperbilirubinemia with indinavir

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this